How do doctors and researchers measure eczema?

We are all numbers when it comes to eczema. 

0-4 to be exact. 

The ISGA, or Investigator’s Static Global Assessment, is a five-point scale that provides a clinical assessment of atopic dermatitis severity ranging from 0 to 4. 

  • 0 indicates clear
  • 1 is almost clear
  • 2 is mild
  • 3 is moderate
  • 4 indicates severe. 


The lower the score, the better. A well-managed eczema patient is a patient at a 0-1 on the ISGA scale, and a successful therapy is typically regarded as one that safely and effectively reduces scores at least 2 points, ideally to an ISGA of 0-1. The length of time is very much product and study dependent; steroids are often evaluated over as little as 4 weeks while injectable biologics can be evaluated over 16 weeks. 

As I like to teach via example, please see this public link for reference. Inside, you will see study results from a popular non-steroid topical indicated for mild to moderate eczema, or eczema that begins at an ISGA between 1 and 3. 

Watch for more updates in the coming days. There’s a reason I’m teaching you this beyond just loving to create more educated patients, caregivers, and investors.

Related News

Sign Up for Updates

Enter your information to receive the latest product updates and news from Turn Therapeutics.

Muhammad Zubair

Controller

Zubair, Controller, has 5+ years of accounting and finance management experience in companies ranging from medium-sized companies to pulicly traded multinationals. Zubair is a member of the Institute of Chartered Accountants of Pakistan and holds a Master’s degree in accounting & finance (Equivalent). 

Zuraiz Chaudhary, CPA

Chief Accounting Officer, VP Finance

Zuraiz, VP of Finance and Chief Accounting Officer, is a seasoned finance & accounting executive with more than a decade experience in working with PwC, EY and KPMG.  Zuraiz is a licensed CPA in California and Texas, has a bachelor’s in business administration from Asia-e University (Malaysia), is a member of the Institute of Chartered Accountants of Pakistan. Zuraiz specializes in financial reporting, SOX compliance and internal controls.

Dr. Neil Ghodadra, MD

Chief Medical Officer, Board Director

Dr. Neil Ghodadra, Board Certified Orthopedic Surgeon, joined Turn in Q3 2017. Renowned for surgical skill and orthopedic research, he graduated Magna Cum Laude from Duke University with a BS in Biology, and with Honors from Duke Medical School. His residency at Rush Medical Center focused on sports medicine, specializing in knee & shoulder surgery.

Bradley Burnam

Chief Executive Officer & Founder

Bradley Burnam, Founder & CEO, developed PermaFusion®, a patented drug delivery system, to combat his hospital-acquired skin infection. This innovation led to Hexagen™ Wound Dressing, Turn’s flagship product. Burnam, a self-taught regulatory and formulation expert, secured Turn’s first three FDA clearances solo before assembling a skilled team.

Subscribe to the Founder's Blog

Enter your information to subscribe for the latest updates from our Founder’s Blog.